Glucagon-like peptide–1 (GLP-1) has a diverse set of peripheral actions which all serve to promote enhanced glucose tolerance, and for this reason it has become the basis for new treatments for type 2 diabetes. In this issue of the JCI, Knauf et al. provide clear evidence that GLP-1 signaling in the CNS is also linked to the control of peripheral glucose homeostasis by inhibiting non–insulin-mediated glucose uptake by muscle and increasing insulin secretion from the pancreas. The authors’ work points to an important need to integrate diverse GLP-1 signaling actions and peripheral GLP-1 function in order to better understand both normal and abnormal glucose homeostasis.
David A. D’Alessio, Darleen A. Sandoval, Randy J. Seeley
Title and authors | Publication | Year |
---|---|---|
Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors
J Zhong, A Maiseyeu, S Rajagopalan |
Clinical Lipidology | 2015 |
Peripheral Signals Mediate the Beneficial Effects of Gastric Surgery in Obesity
S Barja-Fernández, C Folgueira, C Castelao, R Leis, FF Casanueva, LM Seoane |
Gastroenterology Research and Practice | 2015 |
Phenotyping of type 2 diabetes mellitus at onset on the basis of fasting incretin tone: Results of a two-step cluster analysis.
Amato MC, Pizzolanti G, Torregrossa V, Pantò F, Giordano C |
Journal of Diabetes Investigation | 2015 |